Haematologica · 2019 · 50 citations · 43 references
MedicineHematologyOncologyApoptosisMolecular OncologyProtein-protein InteractionsApoptosis In CancerApoptosis ResistanceBcl-2 Family ProteinsHematologic Malignancy TherapyLymphoid NeoplasmsAnti-apoptotic Bcl-2 Protein InhibitionAnti-apoptotic ProteinsBcl-2 Protein ExpressionPro-apoptotic Bcl-2 ProteinsPro-apoptotic ProteinsProapoptotic Bcl-2 ProteinsProtein Expression LevelsRegulation By Bcl-2 Family Proteins
The BCL-2-specific inhibitor, ABT-199 (venetoclax) has exhibited remarkable clinical activity in nearly all cases of chronic lymphocytic leukemia. In contrast, responses are usually much less in diffuse large B-cell lymphoma (DLBCL), despite high level expression of BCL-2 in over 40% of cases, indicating that co-expression of related anti-apoptotic BCL-2 family proteins may limit the activity of ABT-199. We have investigated the roles of BCL-2 proteins in DLBCL cells using a panel of specific BCL-2 homology 3 (BH3)-mimetics and identified subgroups of these cells that exhibited marked and specific dependency on either BCL-2, BCL-XL or MCL-1 for survival. Dependency was associated with selective sequestration of the pro-apoptotic proteins BIM, BAX and BAK by the specific anti-apoptotic BCL-2 protein which was important for cellular survival. Sensitivity to BH3-mimetics was independent of genetic alterations involving the BCL-2 family and only partially correlated with protein expression levels. Treatment with ABT-199 displaced BAX and BIM from BCL-2, subsequently leading to BAK activation and apoptosis. In contrast, apoptosis induced by inhibiting BCL-XL with A1331852 was associated with a displacement of both BAX and BAK from BCL-XL and occurred independently of BIM. Finally, the MCL-1 inhibitor S63845 induced mainly BAX-dependent apoptosis mediated by a displacement of BAK, BIM and NOXA from MCL-1. In conclusion, our study indicates that in DLBCL, the heterogeneous response to BH3-mimetics is mediated by selective interactions between BAX, BAK and anti-apoptotic BCL-2 proteins.
43
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Ash A. Alizadeh, Michael B. Eisen, R. Eric Davis et al. · Nature · 2000 · 10K citations
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
Roland Schmitz, George W. Wright, Da Wei Huang et al. · New England Journal of Medicine · 2018 · 2.3K citations · Full text